Therapies aimed at airway inflammation in cystic fibrosis.
Therapies aimed at decreasing the inflammatory response present a new strategy for treating cystic fibrosis (CF) lung disease. Alternate day prednisone may be beneficial, however, unacceptable adverse effects limit long-term use. Inhaled corticosteroids are under investigation as a safer alternative. High-dose ibuprofen twice daily has been shown to decrease the progression of CF lung disease and is without significant toxicity. Other NSAIDs and pentoxifylline and fish oil are under consideration. Antiproteases and antioxidants are also being studied. The rationale for all of these agents lies in their potential to decrease neutrophil influx into the lung, and counteract injurious products of neutrophils. Adding anti-inflammatory therapy to an already comprehensive treatment program will hopefully decrease morbidity and improve the quality of life for patients with CF.
Konstan
M W
MW
Department of Pediatrics, Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
D000894:Anti-Inflammatory Agents, Non-Steroidal / Q000627:therapeutic use; D003550:Cystic Fibrosis / Q000503:physiopathology / Q000628:therapy*; D005938:Glucocorticoids / Q000627:therapeutic use; D006801:Humans; D007052:Ibuprofen / Q000627:therapeutic use; D066298:In Vitro Techniques; D007249:Inflammation / Q000628:therapy; D009504:Neutrophils / Q000187:drug effects / Q000502:physiology; D016896:Treatment Outcome
D000894:Anti-Inflammatory Agents, Non-Steroidal; D005938:Glucocorticoids; D007052:Ibuprofen